79 related articles for article (PubMed ID: 29366664)
1. Brain disposition, metabolism and behavioral effects of the synthetic opioid AH-7921 in rats.
Lucchetti J; Marzo CM; Passoni A; Moro F; di Clemente A; Bagnati R; Cervo L; Gobbi M
Neuropharmacology; 2018 May; 133():51-62. PubMed ID: 29366664
[TBL] [Abstract][Full Text] [Related]
2. Brain Disposition of
Lucchetti J; Marzo CM; Passoni A; Di Clemente A; Moro F; Bagnati R; Gobbi M; Cervo L
J Pharmacol Exp Ther; 2017 Jun; 361(3):492-500. PubMed ID: 28404688
[No Abstract] [Full Text] [Related]
3. Fatal intoxications associated with the designer opioid AH-7921.
Kronstrand R; Thelander G; Lindstedt D; Roman M; Kugelberg FC
J Anal Toxicol; 2014 Oct; 38(8):599-604. PubMed ID: 25217553
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male rats.
Truver MT; Smith CR; Garibay N; Kopajtic TA; Swortwood MJ; Baumann MH
Neuropharmacology; 2020 Oct; 177():108195. PubMed ID: 32533977
[TBL] [Abstract][Full Text] [Related]
5. Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation.
Wohlfarth A; Scheidweiler KB; Pang S; Zhu M; Castaneto M; Kronstrand R; Huestis MA
Drug Test Anal; 2016 Aug; 8(8):779-91. PubMed ID: 26331297
[TBL] [Abstract][Full Text] [Related]
6. Morphine sex-dependently induced place conditioning in adult Wistar rats.
Karami M; Zarrindast MR
Eur J Pharmacol; 2008 Mar; 582(1-3):78-87. PubMed ID: 18191832
[TBL] [Abstract][Full Text] [Related]
7. Glycyl-glutamine, an endogenous beta-endorphin-derived peptide, inhibits morphine-induced conditioned place preference, tolerance, dependence, and withdrawal.
Cavun S; Göktalay G; Millington WR
J Pharmacol Exp Ther; 2005 Nov; 315(2):949-58. PubMed ID: 16079299
[TBL] [Abstract][Full Text] [Related]
8. Structure identification and elucidation of mosapride metabolites in human urine, feces and plasma by ultra performance liquid chromatography-tandem mass spectrometry method.
Sun X; Zhao L; Niu L; Qin F; Lu X; Xiong Z; Li F
Xenobiotica; 2014 Aug; 44(8):734-42. PubMed ID: 24417754
[TBL] [Abstract][Full Text] [Related]
9. Repeated pre-exposure to morphine into the ventral pallidum enhances morphine-induced place preference: involvement of dopaminergic and opioidergic mechanisms.
Zarrindast MR; Ebrahimi-Ghiri M; Rostami P; Rezayof A
Behav Brain Res; 2007 Jul; 181(1):35-41. PubMed ID: 17451818
[TBL] [Abstract][Full Text] [Related]
10. Psychopharmacological characterization of an emerging drug of abuse, a synthetic opioid U-47700, in adult zebrafish.
Kolesnikova TO; Shevyrin VA; Eltsov OS; Khatsko SL; Demin KA; Galstyan DS; de Abreu MS; Kalueff AV
Brain Res Bull; 2021 Feb; 167():48-55. PubMed ID: 33249261
[TBL] [Abstract][Full Text] [Related]
11. Morphine-induced place preference: involvement of cholinergic receptors of the ventral tegmental area.
Rezayof A; Nazari-Serenjeh F; Zarrindast MR; Sepehri H; Delphi L
Eur J Pharmacol; 2007 May; 562(1-2):92-102. PubMed ID: 17336285
[TBL] [Abstract][Full Text] [Related]
12. Effects of μ-opioid receptor agonists in assays of acute pain-stimulated and pain-depressed behavior in male rats: role of μ-agonist efficacy and noxious stimulus intensity.
Altarifi AA; Rice KC; Negus SS
J Pharmacol Exp Ther; 2015 Feb; 352(2):208-17. PubMed ID: 25406170
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of glycine transporter 1 attenuates nicotine- but not food-induced cue-potentiated reinstatement for a response previously paired with sucrose.
Uslaner JM; Drott JT; Sharik SS; Theberge CR; Sur C; Zeng Z; Williams DL; Hutson PH
Behav Brain Res; 2010 Feb; 207(1):37-43. PubMed ID: 19799936
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
Lalovic B; Kharasch E; Hoffer C; Risler L; Liu-Chen LY; Shen DD
Clin Pharmacol Ther; 2006 May; 79(5):461-79. PubMed ID: 16678548
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats.
Elmore JS; Dillon-Carter O; Partilla JS; Ellefsen KN; Concheiro M; Suzuki M; Rice KC; Huestis MA; Baumann MH
Neuropsychopharmacology; 2017 Feb; 42(3):649-660. PubMed ID: 27658484
[TBL] [Abstract][Full Text] [Related]
16. Rewarding and reinforcing effects of 4-chloro-2,5-dimethoxyamphetamine and AH-7921 in rodents.
Cha HJ; Jeon SY; Jang HJ; Shin J; Kim YH; Suh SK
Neurosci Lett; 2018 May; 676():66-70. PubMed ID: 29626650
[TBL] [Abstract][Full Text] [Related]
17. DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. II. A mixed opioid agonist with potent antinociceptive activity and limited effects on respiratory function.
Gengo PJ; Pettit HO; O'Neill SJ; Su YF; McNutt R; Chang KJ
J Pharmacol Exp Ther; 2003 Dec; 307(3):1227-33. PubMed ID: 14534367
[TBL] [Abstract][Full Text] [Related]
18. Effect of 12-oxochenodeoxycholate on the pharmacokinetics and pharmacodynamics of morphine 6-glucuronide in Wistar rats.
Yang L; Fawcett JP; Zhang H; Tucker IG
J Pharm Pharmacol; 2013 Apr; 65(4):561-6. PubMed ID: 23488785
[TBL] [Abstract][Full Text] [Related]
19. Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward.
Braida D; Limonta V; Capurro V; Fadda P; Rubino T; Mascia P; Zani A; Gori E; Fratta W; Parolaro D; Sala M
Biol Psychiatry; 2008 Feb; 63(3):286-92. PubMed ID: 17920565
[TBL] [Abstract][Full Text] [Related]
20. Chronic muscle pain induced by repeated acid Injection is reversed by spinally administered mu- and delta-, but not kappa-, opioid receptor agonists.
Sluka KA; Rohlwing JJ; Bussey RA; Eikenberry SA; Wilken JM
J Pharmacol Exp Ther; 2002 Sep; 302(3):1146-50. PubMed ID: 12183674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
